Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials.

Hepatology (Baltimore, Md.) - 1 Feb 2005

Chalasani Naga, Manzarbeitia Cosme, Ferenci Peter, Vogel Wolfgang, Fontana Robert J, Voigt Michael, Riely Caroline, Martin Paul, Teperman Lewis, Jiao James, Lopez-Talavera Juan Carlos

Abstract excerpt

There is currently no effective treatment for recurrent hepatitis C after orthotopic liver transplantation (OLT). We therefore performed two randomized, controlled trials--a prophylaxis trial and a treatment trial--to evaluate the safety and efficacy of peginterferon alfa-2a in patients who had undergone OLT. The prophylaxis trial enrolled 54 patients within 3 weeks after OLT, and the treatment trial enrolled 67...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferon-alpha
Share to Hepatitis C

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Liver Transplantation

Share to Polyethylene Glycols

Share to Postoperative Period

Share to Predictive Value of Tests

Share to Secondary Prevention

Source

Identifiers

PMID: 15660392
DOI: 10.1002/hep.20560

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials.PMID 15660392Read ↗

A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.Semantic proximity Read ↗

Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study.Semantic proximity Read ↗

Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options.Semantic proximity Read ↗

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.Semantic proximity Read ↗

Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.Semantic proximity Read ↗

Hepatitis C treatment in patients on the liver transplant waiting list.Semantic proximity Read ↗

Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.Semantic proximity Read ↗

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Semantic proximity Read ↗

Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin.Semantic proximity Read ↗

Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease.Semantic proximity Read ↗

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.Semantic proximity Read ↗

Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.